Status:
COMPLETED
Optos P200TE Agreement and Precision Study
Lead Sponsor:
Optos, PLC
Conditions:
Retinal Disease
Glaucoma
Eligibility:
All Genders
22+ years
Phase:
NA
Brief Summary
This study is a prospective comparative, randomized, single center study to assess agreement and precision of the Optos P200TE in comparison to the predicate device in normal subjects, subjects with g...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Normal Group
- Subjects 22 years of age or older on the date of informed consent
- Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- Subjects with normal eye examinations in both eyes on the date of the study visit as observed with a 90 diopter lens
- BCVA 20/40 or better (each eye) on the date of the study visit
- Exclusion Criteria for Normal Group
- Subjects unable to tolerate ophthalmic imaging
- Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in either eye
- Presence of any ocular pathology except for cataract in either eye
- History of leukemia, dementia or multiple sclerosis
- Inclusion Criteria for Glaucoma Group
- Subjects 22 years of age or older on the date of informed consent
- Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- BCVA 20/40 or better in the study eye
- History of Visual field defects within the previous six (6) months from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
- On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
- Glaucoma hemi-field test "outside normal limits."
- Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
- Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
- Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
- Exclusion Criteria for Glaucoma Group
- Subjects unable to tolerate ophthalmic imaging
- Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye
- No reliable Humphrey Field Analyzer (HFA) visual field (24-2 Sita Standard, white on white) result within 6 months of the study visit, defined as fixation losses \> 33% or false positives \> 33%, or false negatives \> 33% in the study eye
- Presence of any ocular pathology except glaucoma in the study eye
- History of leukemia, dementia or multiple sclerosis
- Inclusion Criteria for Retina Disease Group
- Subjects 22 years of age or older on the date of informed consent
- Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- Subjects presenting at the site with retinal disease
- BCVA 20/400 or better in the study eye
- Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including patients with drusen and geographic atropy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others
- Exclusion Criteria for Retinal Disease Group
- Subjects unable to tolerate ophthalmic imaging
- Subject with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye
- Presence of glaucoma or any ocular pathology other than a retinal pathology (e.g., cornea pathology) in the study eye as determined by self-report and/or investigator assessment at the study visit;
- History of leukemia, dementia or multiple sclerosis
Exclusion
Key Trial Info
Start Date :
February 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2019
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT03868462
Start Date
February 11 2019
End Date
September 16 2019
Last Update
October 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New England Retina Consultants
Springfield, Massachusetts, United States, 01107